Market cap
$3,728 Mln
Revenue (TTM)
$31 Mln
P/E Ratio
--
P/B Ratio
12.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-63 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-40.2
-
Debt to Equity
0.4
-
Book Value
$2.8
-
EPS
$-1
-
Face value
--
-
Shares outstanding
114,785,000
10 Years Aggregate
CFO
$-511.04 Mln
EBITDA
$-599.12 Mln
Net Profit
$-641.97 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
| 37.5 | 0.8 | 40.7 | 283.5 | 93.5 | 22.2 | 15.8 |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
| 276.7 | 85.5 | -41.1 | 192.9 | -75.1 | -14.4 | 431.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cymabay Therapeu (CBAY)
|
32.5 | 3,728.2 | 31.1 | -105.4 | -315.3 | -64.2 | -- | 12.8 |
| 11.1 | 27.8 | 0.1 | -14.8 | -8,225.6 | 252.1 | -- | 5.1 |
Shareholding Pattern
View DetailsAbout Cymabay Therapeu (CBAY)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome... proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc. Read more
-
President, CEO & Director
Mr. Sujal A. Shah
-
President, CEO & Director
Mr. Sujal A. Shah
-
Headquarters
Fremont, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cymabay Therapeu (CBAY)
What is the current share price of Cymabay Therapeu (CBAY) Today?
The share price of Cymabay Therapeu (CBAY) is $32.48 (NASDAQ) as of 25-Mar-2024 09:30 EDT. Cymabay Therapeu (CBAY) has given a return of 93.54% in the last 3 years.
What is the current PB & PE ratio of Cymabay Therapeu (CBAY)?
Since, TTM earnings of Cymabay Therapeu (CBAY) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-23.76
|
8.57
|
|
2022
|
-4.64
|
15.26
|
|
2021
|
-2.59
|
1.81
|
|
2020
|
-8.14
|
2.78
|
|
2019
|
-1.28
|
0.70
|
What is the 52 Week High and Low of Cymabay Therapeu (CBAY)?
The 52-week high and low of Cymabay Therapeu (CBAY) are Rs -- and Rs -- as of 22-Jun-2026.
What is the market cap of Cymabay Therapeu (CBAY)?
Cymabay Therapeu (CBAY) has a market capitalisation of $ 3,728 Mln as on 25-Mar-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Cymabay Therapeu (CBAY)?
Before investing in Cymabay Therapeu (CBAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.